...
机译:Pembrolizumab Plus Axitinib与unitinib进行晚期肾细胞癌
Cleveland Clin Taussig Canc Inst 9500 Euclid Ave Desk CA60 Cleveland OH 44195 USA;
Fox Chase Canc Ctr 7701 Burholme Ave Philadelphia PA 19111 USA;
Minist Hlth Ukraine Dnipropetrovsk Med Acad Dnipro Ukraine;
Russian Sci Ctr Roentgen Radiol Moscow Russia;
Christie NHS Fdn Trust Manchester Lancs England;
Cent Clin Hosp Outpatient Clin Moscow Russia;
Ctr Hosp Univ CHU Quebec Quebec City PQ Canada;
Hertzen Moscow Canc Res Inst Moscow Russia;
CHU Montreal Montreal PQ Canada;
Palacky Univ Med Sch &
Teaching Hosp Olomouc Czech Republic;
Sumy State Univ Sumy Reg Oncol Ctr Sumy Ukraine;
Ivano Frankivsk Natl Med Univ Ivano Frankivsk Ukraine;
Dnipropetrovsk Med Acad Dnipro Ukraine;
Hosp Clin Porto Alegre Porto Alegre RS Brazil;
Univ Cote Azur Ctr Antoine Lacassagne Nice France;
Mil Inst Med Warsaw Poland;
Rocky Mt Canc Ctr Colorado Springs CO USA;
Adelaide &
Meath Hosp Dublin Ireland;
Eberhard Karls Univ Tubingen Dept Urol Tubingen Germany;
Hop Univ Lyon Lyon France;
Taipei Vet Gen Hosp Taipei Taiwan;
Osaka City Univ Hosp Osaka Japan;
MSD China Beijing Peoples R China;
Merck Kenilworth NJ USA;
Merck Kenilworth NJ USA;
Georgetown Lombardi Comprehens Canc Ctr Washington DC USA;
Barts Hlth NHS Trust Barts Canc Inst London England;
机译:Pembrolizumab Plus Axitinib与unitinib进行晚期肾细胞癌
机译:Avelumab Plus Axitinib对舒尼替尼用于晚期肾细胞癌
机译:Pembrolizumab Plus Axitinib与Sunitinib的成本效益作为美国晚期肾细胞癌中的一线治疗。
机译:新的DCE-MRI参数可量化舒尼替尼治疗在肾癌肿瘤中诱导的血管变化
机译:晚期浆液性卵巢癌的同型TP53突变。
机译:成本效益分析:一线Avelumab加阿昔替尼与舒尼替尼治疗晚期肾细胞癌
机译:一种成本效益分析:一线Avelumab Plus Axitinib与仙醇进行晚期肾细胞癌